LUCIANO MOREIRA BARACIOLI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
conferenceObject Economic analysis of platelet aggregability-guided surgical revascularization compared with standard of care in ACS patients: subanalysis from PLAT-CABG randomized clinical trial(2020) NAKASHIMA, C. A. K.; DALIAN, L. A. O.; LISBOA, L. A. F.; JATENE, F. B.; SOEIRO, A. M.; NAJJAR, L. A.; SILVA, B. A.; DORNAS, C. J. C. B.; DALCOQUIO, T. F.; FURTADO, R. H. M.; BARACIOLI, L. M.; FUKUSHIMA, J. T.; GURBEL, P. A.; GIUGLIANO, R. P.; NICOLAU, J. C.conferenceObject EFFECT OF EXERCISE TRAINING ON PLATELET AGGREGATION AND ON P2Y12 INHIBITOR RESISTANCE AFTER MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL(2020) DALCOQUIO, Talia; FURTADO, Remo Holanda de Mendonca; ARANTES, Flavia Bittar Britto Britto; SANTOS, Mayara Alves dos; ALVES, Leandro Silva; RONDON, Maria Urbana Pinto Brandao; FERREIRA-SANTOS, Larissa; ALVES, Maria Janieire de Nazare Nunes; FERRARI, Aline Gehlen; GENESTRETI, Paulo Rizzo; BARACIOLI, Luciano Moreira; FRANCI, Andre; SALSOSO, Rocio; NEGRAO, Carlos Eduardo; NICOLAU, Jose CarlosconferenceObject Platelet reactivity among patients with acute coronary syndromes and multivessel coronary artery disease(2020) FURTADO, R.; SALSOSO, R.; DALCOQUIO, T. F.; DOMINGUES, A. A.; NAKASHIMA, C. A. K.; PEREIRA, C. A. C.; V, R. R. C. Giraldez; LIMA, F. G.; MELO, R. R.; FERRARI, A. G.; GENESTRETI, P. R. R.; BARACIOLI, L. M.; NICOLAU, J. C.- Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease(2020) SALSOSO, Rocio; DALCOQUIO, Talia F.; FURTADO, Remo H. M.; FRANCI, Andre; BARBOSA, Carlos J. D. G.; GENESTRETI, Paulo R. R.; STRUNZ, Celia M. C.; LIMA, Viviane; BARACIOLI, Luciano M.; GIUGLIANO, Robert P.; GOODMAN, Shaun G.; GURBEL, Paul A.; MARANHAO, Raul C.; NICOLAU, Jose C.Introduction Lipoprotein (a) [Lp(a)] is a risk factor for coronary artery disease (CAD). To the best of our knowledge, this is the first study addressing the relationship between Lp(a) and platelet reactivity in primary and secondary prevention. Methods Lp(a) was evaluated in 396 individuals with (82.3%) and without (17.7%) obstructive CAD. The population was divided into two groups according to Lp(a) concentrations with a cutoff value of 50 mg/dL. The primary objective was to evaluate the association between Lp(a) and adenosine diphosphate (ADP)-induced platelet reactivity using the VerifyNow (TM) P2Y(12)assay. Platelet reactivity was also induced by arachidonic acid and collagen-epinephrine (C-EPI) and assessed by Multiplate (TM), platelet function analyzer (TM) 100 (PFA-100), and light transmission aggregometry (LTA) assays. Secondary objectives included the assessment of the primary endpoint in individuals with or without CAD. Results Overall, 294 (74.2%) individuals had Lp(a) < 50 mg/dL [median (IQR) 13.2 (5.8-27.9) mg/dL] and 102 (25.8%) had Lp(a) >= 50 mg/dL [82.5 (67.6-114.5) mg/dL],P < 0.001. Univariate analysis in the entire population revealed no differences in ADP-induced platelet reactivity between individuals with Lp(a) >= 50 mg/dL (249.4 +/- 43.8 PRU) versus Lp(a) < 50 mg/dL (243.1 +/- 52.2 PRU),P = 0.277. Similar findings were present in individuals with (P = 0.228) and without (P = 0.669) CAD, and regardless of the agonist used or method of analysis (allP > 0.05). Finally, multivariable analysis did not show a significant association between ADP-induced platelet reactivity and Lp(a) >= 50 mg/dL [adjusted OR = 1.00 [(95% CI 0.99-1.01),P = 0.590]. Conclusion In individuals with or without CAD, Lp(a) >= 50 mg/dL was not associated with higher platelet reactivity.
conferenceObject Intravenous glycoprotein IIbIIIa inhibitor bridging for urgent coronary artery bypass graft after acute coronary syndrome(2020) FERREIRA, M. R. C.; BARACIOLI, L. M.; DALCOQUIO, T.; NAKASHIMA, C. A. K.; SOFFIALLI, C. D.; BERTOLIN, A. J.; MUSTAFA, S.; I, D. Sobreiro; BALDO, V. M. G. T. F.; PEREIRA, C. A. C.; SALSOSO, R.; LIMA, F. G.; FRANCI, A.; FURTADO, R. H. M.; NICOLAU, J. C.- Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial(2020) ARANTES, Flavia B. B.; MENEZES, Fernando R.; FRANCI, Andre; BARBOSA, Carlos J. D. G.; DALCOQUIO, Talia F.; NAKASHIMA, Carlos A. K.; BARACIOLI, Luciano M.; FURTADO, Remo H. M.; NOMELINI, Quintiliano S. S.; RAMIRES, Jose A. F.; KALIL FILHO, Roberto; NICOLAU, Jose C.Introduction The interaction between anticoagulants and platelet function is complex. Previous publications showed mixed results regarding the role of heparins in platelet aggregation. On the other hand, the direct thrombin inhibitor (DTI) dabigatran might enhance the risk of myocardial infarction in patients with atrial fibrillation, which could be related to increased platelet aggregability. Methods This was a prospective, interventional study of patients with chronic coronary artery disease (CAD) taking low-dose aspirin. The objective of the current study was to compare the effects of dabigatran versus enoxaparin on platelet aggregability. Subjects initially were on orally administered dabigatran for 5 days followed by subcutaneously administered enoxaparin after a 30-day washout period. Platelet function was assessed at baseline and after each intervention by multiple electrode aggregometry (MEA-ASPI) (primary endpoint), serum thromboxane B2 (TXB2), VerifyNow Aspirin (TM), and coagulation tests (secondary endpoints). Results Compared to baseline MEA-ASPI values, dabigatran increased platelet aggregation while enoxaparin decreased platelet aggregation (+ 5 U +/- 24.1 vs - 6 U +/- 22.2, respectively, p = 0.012). The TXB2 assay showed the same pattern (+ 2 pg/ml for dabigatran vs - 13 pg/ml for enoxaparin, p = 0.011). None of the additional tests showed significant differences between the groups. Individually, compared to baseline TXB2 results, enoxaparin significantly decreased platelet activation [33 (16.5-95) pg/mL vs 20 (10-52) pg/mL, respectively, p = 0.026], but no significant differences were observed with dabigatran. Conclusions DTI and anti-Xa drugs exert opposite effects on platelet function. A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase 1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.
- Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Registry in Acute Coronary SyndromEs)(2020) FRANKEN, Marcelo; GIUGLIANO, Robert P.; GOODMAN, Shaun G.; BARACIOLI, Luciano Moreira; GODOY, Lucas Colombo; FURTADO, Remo H. M.; LIMA, Felipe Gallego; NICOLAU, Jose CarlosAims Diagnostic and therapeutic tools have a significant impact on morbidity and mortality associated with acute coronary syndromes (ACS). Data about ACS performance measures are scarce in Brazil, and improving its collection is an objective of the Brazilian Registry in Acute Coronary syndromEs (BRACE). Methods and results The BRACE is a cross-sectional, observational epidemiological registry of ACS patients. Stratified 'cluster sampling' methodology was adopted to obtain a representative picture of ACS. A performance score (PS) varying from 0 to 100 was developed to compare studied parameters. Performance measures alone and the PS were compared between institutions, and the relationship between the PS and outcomes was evaluated. A total of 1150 patients, median age 63 years, 64% male, from 72 hospitals were included in the registry. The mean PS for the overall population was 65.9% +/- 20.1%. Teaching institutions had a significantly higher PS (71.4% +/- 16.9%) compared with non-teaching hospitals (63.4% +/- 21%; P <0.001). Overall in-hospital mortality was 5.2%, and the variables that correlated independently with in-hospital mortality included: PS perpoint increase (OR = 0.97, 95% CI 0.95-0.98, P < 0.001), age-per year (OR= 1.06, 95% CI 1.03-1.09, P < 0.001), chronic kidney disease (OR = 3.12, 95% CI 1.08-9.00, P = 0.036), and prior angioplasty (OR = 0.25, 95% CI 0.07-0.84, P = 0.025). Conclusions In BRACE, the adoption of evidence-based therapies for ACS, as measured by the performance score, was independently associated with lower in-hospital mortality. The use of diagnostic tools and therapeutic approaches for the management of ACS is less than ideal in Brazil, with high variability especially among different regions of the country.
conferenceObject COMPARISON BETWEEN TWO DIFFERENT LOCAL HEMOSTASIS TECHNIQUES FOR DENTAL EXTRACTIONS IN PATIENTS ON DUAL ANTIPLATELET THERAPY: A WITHIN-PERSON, SINGLE-BLIND, RANDOMIZED TRIAL(2020) GUARDIEIRO, Bruno; SANTOS-PAUL, Marcela A.; SALSOSO, Rocio; DALCOQUIO, Talia; FURTADO, Remo; NEVES, Itamara L. I.; NEVES, Ricardo S.; CAVALHEIRO FILHO, Cyrillo; BARACIOLI, Luciano; NICOLAU, Jose C.conferenceObject IMPACT OF HIGH LIPOPROTEIN(A) LEVELS ON PLATELET AGGREGABILITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE(2020) SALSOSO, Rocio; DALCOQUIO, Talia; FURTADO, Remo; FRANCI, Andre; BARBOSA, Carlos; GENESTRETI, Paulo; FERREIRA, Mayara Reis Cardoso; STRUNZ, Celia; BARACIOLI, Luciano; MARANHAO, Raul Cavalcante; NICOLAU, Jose CarlosconferenceObject ELECTRICAL STORM AND CARDIOGENIC SHOCK AFTER ACUTE CORONARY SYNDROME REVERTED WITH ECMO CASE REPORT(2020) FERREIRA, Mayara Reis Cardoso; BARACIOLI, Luciano Moreira; GALAS, Filomena Regina Barbosa Gomes; DALCOQUIO, Talia; FURTADO, Remo Holanda; BALDO, Vanessa Maria Gomes Taques; SOFFIATTI, Carla David; BERTOLIN, Adriadne Justi; MUSTAFA, Sumaia; SOBREIRO, Daniely Iadocico; NICOLAU, Jose Carlos